335 terminated. 335 Phase 2, 64 Phase 1, 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 335 | Terminated 335 |
| Phase 1 | 64 | Terminated 64 |
| Phase 3 | 15 | Terminated 15 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF) | Phase 2 | Terminated | Genfit | 3 | 2025-08-25 | 2026-01-12 |
| A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence Cadonilimab (AK104) - Hepatocellular Carcinoma (HCC) | Phase 2 | Terminated | Guangxi Medical University | 45 | 2025-02-16 | 2026-02-18 |
| A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 KRRO-110 - Alpha-1 Anti-trypsin Deficiency, AATD | Phase 1 / Phase 2 | Terminated | Korro Bio, Inc. | 42 | 2025-01-13 | 2026-04-17 |
| NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients MAP-Target Algorithm - Acute Kidney Injury, Cirrhosis | Phase 2 / Phase 3 | Terminated | University of California, San Francisco | 14 | 2024-02-01 | 2026-09-24 |
| A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly Placebo, Avenciguat - Hypertension, Portal, Liver Cirrhosis | Phase 2 | Terminated | Boehringer Ingelheim | 22 | 2024-01-03 | 2025-06-12 |
| A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tiragolumab - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 62 | 2023-12-05 | 2026-09-15 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive INCB099280 - Advanced Solid Tumor | Phase 2 | Terminated | Incyte Corporation | 73 | 2023-10-30 | 2026-10-20 |
| LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2023-09-27 | 2026-06-18 |
| Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)® VS-01 on top of SOC, SOC (Control Group) - Acute-On-Chronic Liver Failure, Ascites | Phase 2 | Terminated | Genfit | 15 | 2023-07-02 | 2026-07-23 |
| Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization - Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Phase 2 | Terminated | Yale University | 3 | 2023-06-07 | 2025-01-15 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) Chidamide, Regorafenib - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Great Novel Therapeutics Biotech & Medicals Corporation | 7 | 2023-04-25 | 2025-03-11 |
| Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B STSG-0002 Injection - Chronic Hepatitis b | Phase 2 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 9 | 2023-04-25 | 2023-12-19 |
| To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B STSG-0002 Injection - Chronic Hepatitis b | Phase 2 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 9 | 2023-04-25 | 2023-12-19 |
| A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype VX-864 - Alpha-1 Antitrypsin Deficiency | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 14 | 2023-02-23 | 2025-09-08 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| 18F-DCFPyL PET/CT in Hepatocellular Carcinoma F18-FDG, MRI, CT - Hepatocellular Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2023-01-18 | 2025-08-28 |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study INT-787, Placebo - Alcohol Associated Hepatitis | Phase 2 | Terminated | Intercept Pharmaceuticals | 67 | 2022-12-15 | 2026-05-05 |
| Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma Ezurpimtrostat, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Terminated | University Hospital, Grenoble | 3 | 2022-12-15 | 2025-04-20 |
| Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US Saroglitazar Magnesium 4 mg, Placebo - Nonalcoholic Fatty Liver Disease | Phase 2 | Terminated | Zydus Therapeutics Inc. | 4 | 2022-12-08 | 2025-09-02 |
Showing 20 of 335. Sign in to see all of them.
Carcinoma, Hepatocellular (126) · Non-alcoholic Fatty Liver Disease (46) · Liver Neoplasms (45) · Hepatitis C (33) · Hepatitis B, Chronic (26) · Hepatitis B (23) · Liver Cirrhosis (19) · Fibrosis (18) · Hepatitis C, Chronic (13) · Hypertension, Portal (12) · Liver Cirrhosis, Biliary (12) · Colorectal Neoplasms (10) · Fatty Liver (10) · Hepatitis (10)
Digestive System Diseases (334) · Neoplasms by Site (146) · Digestive System Neoplasms (145) · Neoplasms (140) · Neoplasms by Histologic Type (132) · Neoplasms, Glandular and Epithelial (130) · Adenocarcinoma (128) · Carcinoma (127) · Pathological Conditions, Signs and Symptoms (108) · Liver Neoplasms (101) · Pathologic Processes (100) · Infections (84) · Virus Diseases (82) · Blood-Borne Infections (81)
Sorafenib (15) · Ribavirin (13) · Nivolumab (12) · Tenofovir (12) · entecavir (12) · Bevacizumab (8) · Fluorouracil (8) · atezolizumab (7) · ARC-520 (6) · Radiosurgery (6) · peginterferon alfa-2a (6) · Capecitabine (5) · Doxorubicin (5) · Leucovorin (5) · Oxaliplatin (5)
National Cancer Institute (NCI) (10) · Gilead Sciences (9) · Novartis Pharmaceuticals (8) · Arrowhead Pharmaceuticals (6) · Merck Sharp & Dohme LLC (6) · Assembly Biosciences (5) · Bristol-Myers Squibb (5) · University of Texas Southwestern Medical Center (5) · Emory University (4) · Genfit (4) · Vertex Pharmaceuticals Incorporated (4) · Alexion Pharmaceuticals, Inc. (3) · Boehringer Ingelheim (3) · Bukwang Pharmaceutical (3) · Conatus Pharmaceuticals Inc. (3)
United States (192) · Germany (43) · France (42) · United Kingdom (42) · Canada (40) · South Korea (36) · Taiwan (36) · Spain (34) · China (31) · Italy (26) · Belgium (25) · Australia (21) · Hong Kong (18) · New Zealand (16) · Poland (16)
Hyo Suk Lee, M.D., Ph.D. (3) · Bassel El-Rayes, MD (2) · Daniel T Chang (2) · David Hsieh, MD (2) · Don Mitchell (2) · Guiqiang Wang (2)
PMID 29990488, PMID 31108015, PMID 33307033, PMID 36750244, PMID 37095557, PMID 16628625, PMID 19399502, PMID 19833404, PMID 20724077, PMID 20883560, PMID 22210086, PMID 22913492, PMID 23316013, PMID 23331661, PMID 23356386, PMID 23362324, PMID 23397536, PMID 23664631, PMID 24012941, PMID 24251922, PMID 24512954, PMID 24657396, PMID 24995515, PMID 25173458, PMID 25500425, PMID 25543678, PMID 26449224, PMID 27219495, PMID 27681866, PMID 27788579, PMID 28687627, PMID 28688129, PMID 28818518, PMID 29091342, PMID 29486918, PMID 29509992, PMID 29718334, PMID 30739366, PMID 31680011, PMID 32234329, PMID 32406487, PMID 33011075, PMID 33016924, PMID 33244872, PMID 33712437, PMID 33793651, PMID 34029994, PMID 35043976, PMID 35258371, PMID 35779659
2019 (8), 2018 (5), 2015 (4), 2016 (4), 2017 (4), 2014 (3), 2023 (3), N01CM62201 (2), P30CA033572 (2), U01AA021788 (2), 2008 (1), 2025 (1), N01CM00038 (1), N01CM00070 (1), N01CM62209 (1)